Bio/Pharma Business

Protecting intellectual property rights is vital to biopharmaceutical innovation.

ASCO meeting attendees give artistic interpretations of cancer journeys in the form of public Hope Murals.

Pfizer and the Avon Foundation for Women Breast Cancer Grants Program will award up to $1 million in grants to advocacy, academic, and other not-for-profit organizations.

GSK reports 5-year vaccine price freeze for countries graduating from GAVI Alliance.

Kymab receives $40 million investment for clinical development of antibody therapeutics.

AstraZeneca rejects Pfizer's final offer of $118 billion for a proposed merger of the two companies.

Tigermed acquires Frontage Laboratories for $50.25 million.

The Fogarty International Center, a component of the US NIH, calls for a focus on noncommunicable diseases and implementing science in low-resource settings.

Janssen Pharmaceutical collaborates with Stop TB Partnership's Global Drug Facility to increase access to anti-TB compound.

Bristol-Myers Squibb is named No. 1 on 2014 Best Corporate Citizens List for the third time in six years.

Eli Lilly has developed the Lilly Medical Student Intern Program for future physicians.

Novartis' eBook features images of meningococcal disease survivors from around the world.

UPM will commercially manufacture two ANDA products for Amerigen Pharmaceuticals.

Portfolio swaps between Novartis and GSK involve oncology, vaccines, and consumer products.

Sun Pharma acquisition of Ranbaxy Laboratories will create the fifth-largest specialty generics company in the world.

The I'm In campaign is designed to increase participation by diverse patient populations for clinical trials.

Crystal Pharmatech selects Freeslate for its CM Protege PharmD System.

Lilly Diabetes supports the American Diabetes Association for the seventh year in a row.

Croda receives two achievements in relation to EXCiPACT.

MedImmune and AstraZeneca enter a three-year collaboration with the Clinical and Translational Science Institute at the UC San Francisco.

AbbVie launches art initiative designed to explore impact of chronic inflammatory diseases.

Thirteen companies are accepted for participation in the supply chain program.

Novartis is named among the 2014 Corporate Knights Global 100.

AstraZeneca completes the acquisition of the entirety of BSM's interests in the companies' diabetes alliance.

Vanda Pharmaceuticals receives approval from FDA for Hetlioz for the treatment of Non-24.

AbbVie will open its first manufacturing facility in Singapore.

Thermo Fisher Scientific outlines new business segments with acquisition of Life Technologies.

Pharmaceutical companies are adopting multiple choice partnership strategies to meet the challenges of today's R&D instead of being focused primarily on internal development.

With numerous biologics set to come off patent soon and the percentage of new therapeutics based on biomolecules growing, demand for contract manufacturing in the biopharma space is heating up.

AstraZeneca and Bristol-Myers Squibb Diabetes Alliance provides a $5 million grant to the American Diabetes Association.